Back to Search Start Over

Restrictive vs Liberal Blood Transfusions for Patients With Acute Myocardial Infarction and Anemia by Heart Failure Status: An RCT Subgroup Analysis.

Authors :
Ducrocq G
Cachanado M
Simon T
Puymirat E
Lemesle G
Lattuca B
Ariza-Solé A
Silvain J
Ferrari E
Gonzalez-Juanatey JR
Martínez-Sellés M
Lermusier T
Coste P
Vanzetto G
Cottin Y
Dillinger JG
Calvo G
Steg PG
Source :
The Canadian journal of cardiology [Can J Cardiol] 2024 Sep; Vol. 40 (9), pp. 1705-1714. Date of Electronic Publication: 2024 Feb 24.
Publication Year :
2024

Abstract

Background: Red blood cell transfusion can cause fluid overload. We evaluated the interaction between heart failure (HF) at baseline and transfusion strategy on outcomes in acute myocardial infarction (AMI).<br />Methods: We used data from the randomized REALITY trial. HF was defined as history of HF or Killip class > 1 at randomization. Primary outcome was major adverse cardiovascular events (MACE): composite of all-cause death, nonrecurrent AMI, stroke, or emergency revascularization prompted by ischemia at 30 days.<br />Results: Among 658 randomized patients, 311 (47.3%) had HF. Patients with HF had higher rates of MACE at 30 days and 1 year and higher rates of nonfatal new-onset HF. There was no interaction between HF and effect of randomized assignment on the primary outcome or nonfatal new-onset HF. A liberal transfusion strategy was associated with increased all-cause death at 30 days and at 1 year in patients with HF (P <subscript>interaction</subscript>  = 0.009 and P = 0.049, respectively). The main numerical difference in cause of death between restrictive and liberal strategies was death by HF at 30 days (4 vs 11).<br />Conclusions: HF is frequent in patients with AMI and anemia and is associated with higher risk of MACE (including all-cause death) and nonfatal new-onset HF. Although there was no interaction of HF with effect of transfusion strategy on MACE, a liberal transfusion strategy was associated with higher all-cause death that appears driven by a higher risk of early death caused by HF.<br />Clinical Trial Registration: NCT02648113.<br /> (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1916-7075
Volume :
40
Issue :
9
Database :
MEDLINE
Journal :
The Canadian journal of cardiology
Publication Type :
Academic Journal
Accession number :
38408702
Full Text :
https://doi.org/10.1016/j.cjca.2024.02.013